{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:17:34Z","timestamp":1788283054304,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["NRSA Pre\u2010Doctoral Fellowship"],"award-info":[{"award-number":["NRSA Pre\u2010Doctoral Fellowship"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To compare adherence to tyrosine kinase inhibitors (TKIs) between patients with chronic myeloid leukemia (CML) who initiated branded or generic imatinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used MarketScan commercial claims data (January 2011\u2010June 2018) to identify patients with CML who newly initiated branded imatinib before 1 August 2015 or generic imatinib on or after 2 February 2016, and were continuously enrolled in health plans for 6 months before through 6 months following their initial fill. After inverse probability of treatment weighting, we compared adherence (proportion of days covered [PDC]) and persistence (no gaps \u226530 and \u226560 consecutive days in therapy) to TKI therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients initiating generic imatinib consistently had higher average PDC per month and over the 6\u2010month follow\u2010up period than initiators of branded imatinib. Average 6\u2010month PDC was 92% (95%CI:89%\u201094%) for generic initiators and 85% (95%CI:83%\u201086%) for brand initiators. Compared with branded imatinib initiators, a larger proportion of generic imatinib initiators were adherent and persistent to TKI therapy (PDC \u2265 90%:78% versus 64%; no\u226560\u2010day gap:94% versus 86%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients initiating generic imatinib achieved clinically significant improvements in adherence to TKI therapy relative to branded drug users, presumably due to lower out\u2010of\u2010pocket costs. Given the importance of optimal adherence in CML, considering barriers to adherence (eg, patient\u2010cost sharing and health benefit design) when selecting initial treatment may improve long\u2010term medication adherence. Pharmacoepidemiologic studies should consider how best to account for expected cost\u2010sharing and its impact on adherence and subsequent clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4893","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T08:24:59Z","timestamp":1568190299000},"page":"1529-1533","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6765-8868","authenticated-orcid":false,"given":"Ashley L.","family":"Cole","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Outcomes and Policy UNC Eshelman School of Pharmacy  Chapel Hill North Carolina USA"},{"name":"Cecil G. Sheps Center for Health Services Research  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3467-2502","authenticated-orcid":false,"given":"Shelley A.","family":"Jazowski","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"},{"name":"Department of Population Health Sciences Duke University School of Medicine  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-9196","authenticated-orcid":false,"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy Vanderbilt University School of Medicine  Nashville Tennessee USA"},{"name":"Vanderbilt\u2010Ingram Cancer Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.1684"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0016"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4184"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31050"},{"key":"e_1_2_10_10_1","unstructured":"National Cancer Institute.Financial toxicity and cancer treatment (PDQ\u00ae)\u2014health professional version.https:\/\/www.cancer.gov\/about\u2010cancer\/managing\u2010care\/track\u2010care\u2010costs\/financial\u2010toxicity\u2010hp\u2010pdq. 15April 2019. Accessed 24 May 2019."},{"key":"e_1_2_10_11_1","article-title":"The challenges of high\u2010deductible plans for chronically ill people","author":"Thorpe KE","year":"2019","journal-title":"Health Affairs Blog"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7736"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.4492"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0695-y"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.5.469"},{"key":"e_1_2_10_16_1","unstructured":"CaseyT.Costs and risks associated with specialty medications. First Report Managed Care.https:\/\/www.managedhealthcareconnect.com\/articles\/costs\u2010and\u2010risks\u2010associated\u2010specialty\u2010medications.April 2014. Accessed 24 May 2019."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4893","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:45:12Z","timestamp":1694169912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/pds.4893"],"URL":"https:\/\/doi.org\/10.1002\/pds.4893","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"2019-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}